|
Sign In to gain access to subscriptions and/or personal tools.
|
Valsartan and candesartan can inhibit deteriorating effects of angiotensin II on coronary endothelial function
Harald Seeger
Section of Endocrinology and Menopause, Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany
Caroline Lippert
Section of Endocrinology and Menopause, Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany
Diethelm Wallwiener
Section of Endocrinology and Menopause, Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany
Alfred O Mueck
Section of Endocrinology and Menopause, Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany, endo.meno@ med.uni-tuebingen.de
The angiotensin II (Ang II) AT1-receptor antagonists, valsartan and candesartan, were compared with regard to their effect on Ang II-mediated changes in parameters of coronary endothelial function. Ang II (10 µM) induced increased concentrations of the vasoconstrictor endothelin, the procoagulatory substance plasminogen-activator-inhibitor-1 (PAI-1) and the precursor of the matrix-metalloproteinase 1 (MMP-1) in endothelial cell cultures from human coronary arteries. These increases were completely prevented by the addition of 10 µM valsartan or candesartan and partially by the addition of lower concentrations of these drugs, i.e. 1 µM and 0.1 µM. No significant difference between the effect of the two AT1-receptor antagonists was observed.
These results suggest that AT1-receptor antagonists not only can reduce blood pressure by blocking the action of Ang II, but might also contribute to the prevention of atherogenesis and plaque instability.
Key Words: valsartan candesartan angiotensin II coronary endothelial function
References
- Goodfriend TL, Elliott ME, Catt KJAngiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.[Free Full Text]
- Levin EL Endothelins.NEnglJMed 1995;333:356-63.[Free Full Text]
- Kohler HP, Grant PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease. NEnglJMed 2000;342:1792-801.[Free Full Text]
- Sukhova GK, Schönbeck U., Rabkin E. et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-9.[Abstract/Free Full Text]
- Criscione L., Bradley WA, Bühlmayer P. et al. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995;13:230-50.[CrossRef][Web of Science]
- Nishikawa K., Naka T., Chatani F., Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 1997;11(Suppl.2):S9-S17.[CrossRef]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 2,
141-143 (2001)
DOI: 10.3317/jraas.2001.016

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. E. Striker, F. Praddaude, O. Alcazar, S. W. Cousins, and M. E. Marin-Castano
Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II
Am J Physiol Cell Physiol,
December 1, 2008;
295(6):
C1633 - C1646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Alfakih, R. A. Lawrance, A. Maqbool, K. Walters, S. G. Ball, A. J. Balmforth, and A. S. Hall
The clinical significance of a common, functional, X-linked angiotensin II type 2-receptor gene polymorphism (-1332 G/A) in a cohort of 509 families with premature coronary artery disease
Eur. Heart J.,
March 2, 2005;
26(6):
584 - 589.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Chen, J. Chen, D. Li, X. Zhang, and J. L. Mehta
Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts: Modulation by PPAR-{gamma} Ligand Pioglitazone
Hypertension,
November 1, 2004;
44(5):
655 - 661.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|